Protocol Ledger

Clinical Cooperative Network · Consolidated Sponsor Hub

Canadian Cancer Trials Group: Clinical Trials & FDA Approval Profile

Canadian Cancer Trials Group (Global / Institutional) sponsors 42 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 35 active protocols (21 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.5%
Median Closed Enrollment vs National (145 pts)58 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Canadian Cancer Trials Group
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)42
Active Pipeline (Recruiting Now)35 (21)
Completed vs Stopped Early3 / 4 (9.5%)
Median Closed Actual Enrollment58 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Canadian Cancer Trials Group
Hospital Research SiteLocationShared Protocols
University Health NetworkToronto, Ontario29

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Canadian Cancer Trials Group
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06205485Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal CancerPhase IIIRECRUITING
NCT06880523STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular CarcinomaPhase IIRECRUITING
NCT03550391Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain MetastasePhase IIIRECRUITING
NCT06043427Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal AdenocarcinomaPhase IIRECRUITING
NCT06623461LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced MelanomaPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Canadian Cancer Trials Group Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI